Clinical Trial Update: Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating capecitabine plus camrelizumab for non-pCR triple-negative breast cancer with tumor-infiltrating lymphocytes after neoadjuvant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Capecitabine (capecitabine)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Breast Neoplasms | Phase 3 | Status: RECRUITING